<DOC>
	<DOCNO>NCT01212653</DOCNO>
	<brief_summary>1 . To determine effect Golimumab treatment number function Endothelial Progenitor Cells ( EPCs ) Ankylosing Spondylitis ( AS ) patient possible mechanism effect treatment endothelial function . 2 . To ascertain effect Golimumab treatment , carotid intima-media thickness , vascular stiffness Ankylosing Spondylitis ( AS ) patient measure pulse wave velocity ( PWV ) Augmentation index ( AIx ) . 3 . To assess clinical efficacy Golimumab Chinese Ankylosing Spondylitis ( AS ) patient accord ASAS response criterion month 3 , 6 12 . 4 . To perform cost-effectiveness cost-utility analysis Golimumab Ankylosing Spondylitis ( AS ) patient , use clinic-base data .</brief_summary>
	<brief_title>Effect Anti-TNF ( Alpha ) Treatment Vascular Stiffness Ankylosing Spondylitis ( AS )</brief_title>
	<detailed_description>This study provide important data pathogenesis vascular damage possible mechanism potent anti-inflammatory treatment may reduce cardiovascular risk Ankylosing Spondylitis ( AS ) patient . Fifty patient Ankylosing Spondylitis ( AS ) randomize receive either Golimumab Placebo 12 month . Patients randomize Placebo worsen disease activity ( failure achieve Assessment SpondyloArthritis international Society ( ASAS20 ) ) week 24 permitted escape open-label Golimumab . Clinical assessment , intima-media thickness , vascular stiffness endothelial progenitor cell perform baseline , 6 12 month .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman , 18 year age old Fulfilled modify New York diagnostic criterion Ankylosing spondylitis ( AS ) 3 month Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) ≥ 4 ( 010 point scale ) , Pain visual analog scale ( VAS ) ≥ 4 ( 010cm scale ) Inadequate response least two Nonsteroidal Antiinflammatory Drugs ( NASID ) high recommended dos 3 month unable receive full 3month course intolerance , toxicity contraindication Normal Chest Xray within 3 month baseline Purified Protein Derivative ( PPD ) negative , Latent Tuberculosis ( TB ) patient require therapy Tuberculosis ( TB ) simultaneously first dose study agent Complete ankylosis spine Concurrent inflammatory rheumatic disease Serious infection ( treatment IVinfective ) within 2 month randomization Active Tuberculosis ( TB ) recent contact person active Tuberculosis ( TB ) An opportunistic infection within 6 month screen Known history Hepatitis , Human Immunodeficiency Virus ( HIV ) , Malignancy , transplant organ , multiple sclerosis , congestive heart failure Currently systemic immunosuppressive , DMARDS ( Methotrexate , Sulfasalazine , Hydroxychloroquine ) , Leflunomide within 4 week first study agent Any previous use Alefacept , Efalizumab , Rituximab , Golimumab Natalizumab Use cytotoxic drug , receive intraarticular , intramuscular , intravenous corticosteroid past 4 week screen Clinically significant renal disease ( serum creatinine level ≥ 270µmol/L ) , alanine aminotransferase ( ALT ) ≥ 2 x upper limit normal ( ULN ) Hemoglobin level &lt; 8.5gm/dl , white blood cell count &lt; 3.5x 109/liter , platelet count &lt; 100x 109/liter Female childbearing potential , unwilling use adequate contraception study Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Golimumab</keyword>
	<keyword>Simponi</keyword>
	<keyword>Anti-TNF alpha</keyword>
	<keyword>EPCs</keyword>
	<keyword>Vascular stiffness</keyword>
</DOC>